As of 2025-09-18, the Relative Valuation of Neovacs SA (ALNEV.PA) is (794.03) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.28 EUR, the upside of Neovacs SA based on Relative Valuation is -283682.6%.
The range of the Relative Valuation is (940.85) - (578.29) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 15.4x | 11.0x |
| Forward P/E multiples | 25.1x - 32.1x | 31.4x |
| Fair Price | (940.85) - (578.29) | (794.03) |
| Upside | -336118.7% - -206633.8% | -283682.6% |
| Date | P/E |
| 2025-09-08 | -0.01 |
| 2025-09-05 | -0.02 |
| 2025-09-04 | -0.01 |
| 2025-09-03 | -0.02 |
| 2025-09-02 | -0.02 |
| 2025-09-01 | -0.02 |
| 2025-08-29 | -0.02 |
| 2025-08-28 | -0.02 |
| 2025-08-27 | -0.02 |
| 2025-08-26 | -0.02 |
| 2025-08-25 | -0.02 |
| 2025-08-22 | -0.02 |
| 2025-08-21 | -0.02 |
| 2025-08-20 | -0.02 |
| 2025-08-19 | -0.02 |
| 2025-08-18 | -0.02 |
| 2025-08-15 | -0.02 |
| 2025-08-14 | -0.02 |
| 2025-08-13 | -0.02 |
| 2025-08-12 | -0.02 |
| 2025-08-11 | -0.02 |
| 2025-08-08 | -0.02 |
| 2025-08-07 | -0.02 |
| 2025-08-06 | -0.02 |
| 2025-08-05 | -0.02 |
| 2025-08-04 | -0.03 |
| 2025-08-01 | -0.03 |
| 2025-07-31 | -0.02 |
| 2025-07-30 | -0.03 |
| 2025-07-29 | -0.03 |
| 2025-07-28 | -0.03 |
| 2025-07-25 | -0.03 |
| 2025-07-24 | -0.03 |
| 2025-07-23 | -0.04 |
| 2025-07-22 | -0.04 |
| 2025-07-21 | -0.04 |
| 2025-07-18 | -0.04 |
| 2025-07-17 | -0.05 |
| 2025-07-16 | -0.05 |
| 2025-07-15 | -0.05 |
| 2025-07-14 | -0.06 |
| 2025-07-11 | -0.05 |
| 2025-07-10 | -0.05 |
| 2025-07-09 | -0.05 |
| 2025-07-08 | -0.05 |
| 2025-07-07 | -0.06 |
| 2025-07-04 | -0.06 |
| 2025-07-03 | -0.06 |
| 2025-07-02 | -0.07 |
| 2025-07-01 | -0.06 |